Related Experiment Video
Updated: Aug 14, 2026
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Use of warfarin in non-rheumatic atrial fibrillation: a commentary from general practice
Insights
Warfarin effectively reduces stroke and death risk in atrial fibrillation patients. However, minor bleeding events are common and require careful patient selection and monitoring in primary care.
Area of Science:
- Cardiology
- Pharmacology
- Primary Care Medicine
Background:
- Atrial fibrillation increases stroke risk.
- Warfarin has demonstrated efficacy in reducing ischaemic strokes and mortality in randomized trials.
- Recent guidelines encourage warfarin use in atrial fibrillation patients due to proven benefits.
Purpose of the Study:
- To evaluate the real-world implications of warfarin use in atrial fibrillation, considering bleeding risks and patient selection.
- To provide evidence for stratifying risk in patients with atrial fibrillation for warfarin therapy.
- To inform decision-making models for initiating, continuing, or stopping warfarin in primary care.
Main Methods:
- Systematic review and meta-analysis of seven randomized controlled trials.
- Analysis of major and minor bleeding episode rates in trial populations.
- Examination of patient selection criteria and monitoring protocols in clinical trials versus routine primary care.
- Development of risk stratification models for warfarin therapy.
Main Results:
- Warfarin significantly reduces the risk of ischaemic stroke and death in atrial fibrillation.
- Major bleeding rates in trials were low, but minor bleeding rates were substantially higher.
- Trial populations were highly selected and monitored, potentially not reflecting routine primary care conditions.
- Risk stratification is possible, identifying patients most suitable for warfarin therapy.
Conclusions:
- While warfarin is effective, careful consideration of minor bleeding risks and patient suitability is crucial for primary care.
- Risk stratification models can aid general practitioners in managing warfarin therapy for atrial fibrillation patients.
- Ongoing monitoring and reassessment of risk factors are necessary for safe and effective long-term warfarin use.
Abstract:
Seven randomized trials published in the last six years have shown that warfarin reduces the risk of ischaemic strokes and death in patients with atrial fibrillation. The annual rates of major bleeding episodes in all these trials were low and, as a result, doctors in primary and secondary care are being encouraged to consider using warfarin for patients with atrial fibrillation unless there are obvious contraindications. However, the populations used in these studies were highly selected and rigorously monitored throughout the trial period to minimize the risk of bleeding in a way which probably could not be expected in routine primary care. Although the rates of major bleeding episodes were uniformly low, the rates of minor bleeding episodes were much higher and these could impact substantially on patients' views of the treatment and on the workload of the primary care team. Evidence is now at hand which allows the stratification of risk in patients with atrial fibrillation which should enable those who are at greatest risk to be considered for this form of treatment. Patients may develop risk factors over time which could render them unsuitable for continuation of warfarin therapy. The general practitioner is centrally placed to make the decision about initiating or continuing treatment or indeed stopping it. Several models for decision making in warfarin treatment from primary and secondary care are proposed.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:23Rheumatic Heart Disease I: Introduction
01:21Rheumatic Heart Disease III: Medical Management
01:20Rheumatic Heart Disease IV: Nursing Management
01:29Venous Thrombosis III: Interprofessional Care